FDA approval of lymphoma medicine Ukoniq (umbralisib) is withdrawn due to safety concerns
FDA approval of lymphoma medicine Ukoniq (umbralisib) is withdrawn due to safety concerns
What to do next
Read the issuing agency's notice carefully, compare the product identifiers, and follow the official remedy instructions. RecallDefense helps you keep watch, but the source agency's notice is the authority for action.
Source attribution: FDA. Published Jun 1, 2022.
